Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY-NCGut and Liver

Hepatic Stellate Cells: Fibrogenic Effectors to Central Regulators of Metabolism, Liver Disease Signaling, and Systemic Crosstalk

  1. 1Department of General Surgery (Hepatobiliary Surgery), Biliary-Pancreatic Center, The Affiliated Hospital, Southwest Medical University, Luzhou, China

Abstract

Hepatic stellate cells (HSCs) have long been regarded as the core effector cells in liver fibrosis. The advent of single-cell omics and metabolomics has led to a paradigm shift in our understanding of these cells. Notably, they are not only implicated in local fibrosis but are being increasingly recognized as a hub integrating metabolic and immune signaling. Located at the interface between hepatic vasculature and parenchyma, HSCs have the capacity to modulate intestinal barrier function, neurotransmitter circulation, myocardial energy metabolism, and bone remodeling through metabolic reprogramming (enhanced glycolysis, vitamin A consumption, glutamine metabolism remodeling) and receptor signaling (TLR4, TGF-β, CXCR4, etc.), as well as by secreting metabolites, exosomal miRNAs, and cytokines. Concurrently, HSCs perceive feedback signals from these organs, forming a dynamic cross-organ feedback network. This review systematically integrates the metabolic characteristics of HSCs in diseases such as metabolic dysfunction-associated steatotic liver disease, alcohol-related liver disease, chronic viral hepatitis, and hepatocellular carcinoma, along with their cross-organ interactive effects. We further discuss intervention strategies targeting metabolic pathways, exosomal cargo, and the microbiota-metabolism axis, and propose a three-tier translational framework stratifying HSC-targeted therapeutic approaches by developmental stage, offering novel insights for shifting liver disease treatment from single antifibrotic approaches toward systemic, multi-organ precision interventions.

Related

  1. TLDc proteins: Stress-responsive nexus regulators of redox signaling, V-ATPase dynamics, and organellar crosstalk in neurodegeneration
    Mohammad Sajid Ghufran, Priyanka Soni, Bobby Thomas
    Redox BiologyPeer-reviewedCC BYFull text1 citedEpidemiology & public healthDOAJ
  2. Ductular reaction as a spatial fibrogenic niche: cholangiocyte-macrophage-fibroblast crosstalk in chronic liver disease.
    Kun Wang, Linjun Li, Xiangkun Mei +1
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Impaired immune surveillance of senescent hepatocytes in MASLD: SASP signaling and fibrogenic progression
    Shuhao Cheng, Yinan Zhao, Wei Wang
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossrefEurope PMCPMC
  4. Canonical and Non-Canonical Regulators of Lipid Metabolism in the Liver and the "Liver-Other Organs" Axes.
    Stanislav Kotlyarov, Anna Kotlyarova, Roberto Catanzaro +1
    International journal of molecular sciencesPeer-reviewedCC BYFull textEpidemiology & public healthEurope PMC
  5. MIF-mediated intercellular crosstalk drives antigen-presenting-like cancer-associated fibroblast differentiation in triple-negative breast cancer via TGF-β signaling
    Translational cancer researchPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
BibTeX
@article{li2026hepatic,
  title = {{Hepatic Stellate Cells: Fibrogenic Effectors to Central Regulators of Metabolism, Liver Disease Signaling, and Systemic Crosstalk}},
  author = {Xiang Li and Hao Chen and Wenguang Fu},
  journal = {Gut and Liver},
  year = {2026},
  month = nov,
  doi = {10.5009/gnl260010},
  url = {https://doi.org/10.5009/gnl260010},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - Hepatic Stellate Cells: Fibrogenic Effectors to Central Regulators of Metabolism, Liver Disease Signaling, and Systemic Crosstalk
AU  - Xiang Li
AU  - Hao Chen
AU  - Wenguang Fu
PY  - 2026
DA  - 2026/11/16
JO  - Gut and Liver
DO  - 10.5009/gnl260010
UR  - https://doi.org/10.5009/gnl260010
AB  - Hepatic stellate cells (HSCs) have long been regarded as the core effector cells in liver fibrosis. The advent of single-cell omics and metabolomics has led to a paradigm shift in our understanding of these cells. Notably, they are not only implicated in local fibrosis but are being increasingly recognized as a hub integrating metabolic and immune signaling. Located at the interface between hepatic vasculature and parenchyma, HSCs have the capacity to modulate intestinal barrier function, neurotransmitter circulation, myocardial energy metabolism, and bone remodeling through metabolic reprogramming (enhanced glycolysis, vitamin A consumption, glutamine metabolism remodeling) and receptor signaling (TLR4, TGF-β, CXCR4, etc.), as well as by secreting metabolites, exosomal miRNAs, and cytokines. Concurrently, HSCs perceive feedback signals from these organs, forming a dynamic cross-organ feedback network. This review systematically integrates the metabolic characteristics of HSCs in diseases such as metabolic dysfunction-associated steatotic liver disease, alcohol-related liver disease, chronic viral hepatitis, and hepatocellular carcinoma, along with their cross-organ interactive effects. We further discuss intervention strategies targeting metabolic pathways, exosomal cargo, and the microbiota-metabolism axis, and propose a three-tier translational framework stratifying HSC-targeted therapeutic approaches by developmental stage, offering novel insights for shifting liver disease treatment from single antifibrotic approaches toward systemic, multi-organ precision interventions.
SN  - 1976-2283
SN  - 2005-1212
ER  -